CompletedPhase 2NCT00925054

Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU

Studying Classic phenylketonuria

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
BioMarin Pharmaceutical
Principal Investigator
Ari Gershman, MD, M.D
BioMarin Pharmaceutical
Intervention
rAvPAL-PEG 0.001 mg/kg(drug)
Enrollment
40 enrolled
Eligibility
16-55 years · All sexes
Timeline
20092015

Study locations (11)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00925054 on ClinicalTrials.gov

Other trials for Classic phenylketonuria

Additional recruiting or active studies for the same condition.

See all trials for Classic phenylketonuria

← Back to all trials